Trial Profile
A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects With Active Noninfectious Uveitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2022
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary) ; Prednisone
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
- Acronyms HUMBOLDT
- Sponsors Gilead Sciences
- 30 Apr 2021 Status changed from active, no longer recruiting to discontinued.
- 11 Jan 2021 Planned End Date changed from 1 Jun 2024 to 1 Aug 2021.
- 16 Oct 2020 Status changed from recruiting to active, no longer recruiting.